ライフサイエンスコーパス: leucovorin

1 id (FA) and N(5)-formyltetrahydrofolic acid (leucovorin).

2 e HAI versus systemic bolus fluorouracil and leucovorin.

3 for 3 days before a 5-day course of FU plus leucovorin.

4 sease when they are added to flurouracil and leucovorin.

5 0.8% (five of 628) for bolus weekly 5-FU and leucovorin.

6 treatment with irinotecan, fluorouracil, and leucovorin.

7 e were similar to those for fluorouracil and leucovorin.

8 erved with infusional 5-FU or bolus 5-FU and leucovorin.

9 efractory to treatment with fluorouracil and leucovorin.

10 C85 at 50 mg/d and oral 5-FU with or without leucovorin.

11 IFL [irinotecan and bolus fluorouracil plus leucovorin]).

12 /- 0.01 mM; K(m(FA)), 0.17 +/- 0.02 mM; K(m (leucovorin)), 0.64 +/- 0.23 mM] transport by MRP4.

13 ow-affinity (K(m(FA)), 1.96 +/- 0.13 mM; K(m(leucovorin)), 1.74 +/- 0.65 mM) transport by MRP3.

14 (max (FA)), 0.68 +/- 0.14 nmol/mg/min; V(max(leucovorin)), 1.95 +/- 0.18 nmol/mg/min], low affinity [

15 began treatment with eniluracil (20 mg) and leucovorin (15 mg) (PO bid on days 1 through 3) and 5-FU

16 85 mg/m(2) oxaliplatin infusion over 2 h, L-leucovorin 175 mg or D,L-leucovorin 350 mg infusion over

17 nfusion (HAI) plus systemic fluorouracil and leucovorin, 2-year survival increased to 86%.

18 and (3) fluorouracil (5-FU) 500 mg/m(2) with leucovorin 20 mg/m(2) weekly, weeks 1 to 6 every 8 weeks

19 r square meter as an intravenous bolus), and leucovorin (20 mg per square meter as an intravenous bol

20 er square meter as an intravenous bolus) and leucovorin (20 mg per square meter as an intravenous bol

21 racil (425 mg per square meter per day) plus leucovorin (20 mg per square meter per day) were given o

22 Each cycle of mFOLFOX6 consisted of racemic leucovorin 200 mg/m(2) or 400 mg/m(2), according to the

23 (IV) during 2 hours on day 1, hours 0 to 2; leucovorin 200 mg/m2 IV on days 1 and 2, hours 0 to 2; F

24 ned to receive irinotecan, fluorouracil, and leucovorin; 226 to receive fluorouracil and leucovorin;

25 V(max(FA)), 1.71 +/- 0.05 nmol/mg/min; V(max(leucovorin)), 3.63 +/- 1.20 nmol/mg/min), low-affinity (

26 sion for 4 weeks followed by 1 week of rest; leucovorin 30 mg/m2 administered via intravenous bolus i

27 nfusion over 2 h, L-leucovorin 175 mg or D,L-leucovorin 350 mg infusion over 2 h, and 400 mg/m(2) bol

28 eceived mFOLFOX6 [oxaliplatin 85 mg/m(2) and leucovorin 400 mg/m(2) intravenously followed by fluorou

29 liplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovorin 400 mg/m(2), and bolus fluorouracil 400 mg/m(

30 d on days 15 and 29: oxaliplatin 85 mg/m(2), leucovorin 400 mg/m(2), and fluorouracil 2,000 mg/m(2) i

31 n (180 mg/m(2)), bolus FU (400 mg/m(2)), and leucovorin (400 mg/m(2)) followed by a 46-hour infusion

32 platin, 85 mg/m(2); irinotecan, 180 mg/m(2); leucovorin, 400 mg/m(2); and fluorouracil, 400 mg/m(2) b

33 ens were bolus fluorouracil (5-FU), 5-FU and leucovorin, 5-FU and levamisole, and 5-FU, leucovorin, a

34 n of the MTD of 5-FU given with 776C85, oral leucovorin 50 mg/d on days 2 through 6 was added to dete

35 76C85 10 mg/d with i.v. 5-FU 20 mg/m2/d plus leucovorin 50 mg/d; 776C85 50 mg/d with 5-FU given orall

36 y intravenous [IV] bolus weekly for 6 weeks; leucovorin 500 mg/m(2) IV weekly for 6 weeks of each 8-w

37 travenous (IV) bolus weekly for 6 weeks plus leucovorin 500 mg/m2 IV weekly for 6 weeks during each 8

38 preciably reversed in the presence of excess leucovorin, a hRFC substrate.

39 nd efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly (FOLFOX4) in patients

40 mpounds possessing synergistic activity with leucovorin against colorectal cancer cells.

41 higher response rate than 5-fluorouracil and leucovorin alone.

42 he combined XELOX and FOLFOX groups, and the leucovorin and fluorouracil groups.

43 idence that oxaliplatin plus capecitabine or leucovorin and fluorouracil is the standard of care for

44 mined systemic chemotherapy with FOLFIRINOX (leucovorin and fluorouracil plus irinotecan and oxalipla

45 significantly between patients who received leucovorin and fluorouracil versus those who received ca

46 capecitabine with or without oxaliplatin and leucovorin and fluorouracil with or without oxaliplatin

47 ecitabine with or without oxaliplatin versus leucovorin and fluorouracil with or without oxaliplatin

48 r without oxaliplatin and those who received leucovorin and fluorouracil with or without oxaliplatin.

49 hemotherapy (oxaliplatin and irinotecan plus leucovorin and fluorouracil).

50 for the comparison of XELOX or FOLFOX versus leucovorin and fluorouracil, and was also similar for ca

51 milar for capecitabine-based regimens versus leucovorin and fluorouracil-based regimens (unadjusted p

52 Patients in the fluorouracil-plus-leucovorin and fluorouracil-plus-levamisole groups were

53 luoropyrimidine backbone was capecitabine or leucovorin and fluorouracil.

54 were: XELOX (oxaliplatin and capecitabine); leucovorin and fluorouracil; capecitabine; FOLFOX-4 (leu

55 Early intervention with the combination of leucovorin and glucarpidase is highly effective in patie

56 0089 assessed the relative contributions of leucovorin and levamisole in such patients.

57 nd scheduling, as well as biomodulation with leucovorin and methotrexate.

58 mice were given cisplatin or 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX), and their tumors we

59 oxic effects of 5-fluorouracil combined with leucovorin and to the thymidylate synthase inhibitor, ZD

60 id (FA) and N(5)-formyltetrahydrofolic acid (leucovorin) and that polyglutamylation of MTX abolishes

61 aliplatin plus bolus and infusional 5-FU and leucovorin, and 1.1% (three of 275) for oxaliplatin plus

62 g/m(2) oxaliplatin infusion over 2 h, 200 mg leucovorin, and 400 mg/m(2) bolus fluorouracil followed

63 Plasma MTX, leucovorin, and 5-methyltetrahydrofolate (5-mTHF) concen

64 plus cisplatin (IC), or FOLFOX (oxaliplatin, leucovorin, and bolus and infusional fluorouracil).

65 ceived two cycles of induction fluorouracil, leucovorin, and cisplatin followed by concurrent radiati

66 s of induction chemotherapy of fluorouracil, leucovorin, and cisplatin, followed by 45 Gy of radiatio

67 and oxaliplatin was superior to irinotecan, leucovorin, and fluorouracil as a first-line treatment a

68 de, doxorubicin, methotrexate, fluorouracil, leucovorin, and hormonal synchronization with conjugated

69 y for trans-stimulation by pretreatment with leucovorin, and inhibition by N-hydroxysuccinimide metho

70 apy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, le

71 ) mCRC treated with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab in t

72 ) mCRC treated with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab in t

73 that addition of cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) significantly impro

74 rior efficacy as compared with fluorouracil, leucovorin, and irinotecan (FOLFIRI).

75 leucovorin, and oxaliplatin or fluorouracil, leucovorin, and irinotecan as first-line treatment of ad

76 -line treatment and subsequent fluorouracil, leucovorin, and irinotecan with or without bevacizumab i

77 rred strategy between FOLFIRI (fluorouracil, leucovorin, and irinotecan) and ECX (epirubicin, cisplat

78 n) in study 20050203, FOLFIRI (fluorouracil, leucovorin, and irinotecan) in study 20050181, or best s

79 e that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus

80 rious combinations of adjuvant fluorouracil, leucovorin, and levamisole to determine the ability of t

81 d leucovorin, 5-FU and levamisole, and 5-FU, leucovorin, and levamisole.

82 cizumab to modified infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) 6 regimen for the a

83 n cancer treated with adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy remain

84 months or 6 months of adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) every 2 weeks or ca

85 -year survival with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) of 9.8% was better

86 andom assignment to infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or FOLFOX plus cetu

87 a platinum-based therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) versus a non-platin

88 juvant therapy with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) were randomly assig

89 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based chemotherapy

90 luated preoperative infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX)/bevacizumab with se

91 th stage III CC treated with a fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) regimen.

92 ed with second-line infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4; arm B) versus irin

93 icacy of adding bevacizumab to fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) for the adjuvant t

94 All received infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) combined with bev

95 otherapy using three cycles of fluorouracil, leucovorin, and oxaliplatin before fluorouracil/oxalipla

96 ating the duration of adjuvant fluorouracil, leucovorin, and oxaliplatin or capecitabine and oxalipla

97 th previous reports of either infusional FU, leucovorin, and oxaliplatin or capecitabine and oxalipla

98 mab or cetuximab to infusional fluorouracil, leucovorin, and oxaliplatin or fluorouracil, leucovorin,

99 Infusional fluorouracil, leucovorin, and oxaliplatin was superior to irinotecan,

100 the cost and effectiveness of fluorouracil, leucovorin, and oxaliplatin with or without bevacizumab

101 mFOLFOX6; ie, infusional/bolus fluorouracil, leucovorin, and oxaliplatin) for the adjuvant treatment

102 ned 1:1 to FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) in study 20050203, FOLFIRI

103 nts receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) on study N08CB (North Centr

104 FOLFOX6 (mFOLFOX6; infusional fluorouracil, leucovorin, and oxaliplatin) versus infusional FU/leucov

105 adjuvant therapy with FOLFOX (fluorouracil, leucovorin, and oxaliplatin) were randomly assigned to i

106 RLN), FOLFOX (combination of 5-fluorouracil, leucovorin, and oxaliplatin), and IL-12, successfully st

107 current standard treatment, 5-fluorouracil, leucovorin, and oxaliplatin, in this subgroup remains un

108 n, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevaciz

109 al Cancer] assessed infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin

110 or therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival

111 gery followed by postoperative fluorouracil, leucovorin, and radiotherapy, indicated a significant su

112 leucovorin; 226 to receive fluorouracil and leucovorin; and 226 to receive irinotecan alone.

113 77C, and V380C), inhibition was prevented by leucovorin, another hRFC substrate.

114 Oxaliplatin, fluorouracil, and leucovorin are commonly used to treat advanced and resec

115 MTX, FA, and leucovorin are subject to high capacity [V(max(MTX)), 0.

116 Both FA and leucovorin are subject to high-capacity (V(max(FA)), 1.7

117 covorin with bolus doses of fluorouracil and leucovorin as first-line therapy for metastatic colorect

118 ished alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colore

119 bolus weekly fluorouracil (FU) combined with leucovorin as surgical adjuvant therapy for stage II and

120 Fluorouracil/leucovorin as the sole therapy for metastatic colorectal

121 9 cells treated with ZD9331 or 5fluorouracil/leucovorin, as demonstrated by cDNA microarray analyses.

122 ified FOLFIRINOX (oxaliplatin at 65 mg/m(2), leucovorin at 400 mg/m(2), irinotecan at 140 mg/m(2), an

123 /d with 5-FU given orally at 15 mg/m2/d with leucovorin at 50 mg/d.

124 have comparable activity to fluorouracil and leucovorin, but further studies are needed to assess whe

125 than during treatment with fluorouracil and leucovorin, but the incidence of grade 4 (life-threateni

126 Children with FRAs were treated with oral leucovorin calcium (2 mg kg(-1) per day; maximum 50 mg p

127 iven these results, empirical treatment with leucovorin calcium may be a reasonable and non-invasive

128 studies of folate receptor autoimmunity and leucovorin calcium treatment in children with ASD are wa

129 -positive children with ASD may benefit from leucovorin calcium treatment.

130 m2 of irinotecan hydrochloride, 400 mg/m2 of leucovorin calcium, and then 2400 mg/m2 of 5-fluorouraci

131 , randomized clinical trial of postoperative leucovorin calcium, fluorouracil, irinotecan hydrochlori

132 randomized to adjuvant FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxaliplatin) chem

133 The delivery of PV FUDR and FU with leucovorin can be performed with a high percentage of ex

134 d pyrimidines, including uracil:tegafur plus leucovorin, capecitabine, eniluracil plus oral 5-fluorou

135 patients) or surgery plus fluorouracil (FU)-leucovorin chemotherapy (431 patients) in National Surgi

136 dard adjuvant oxaliplatin, fluorouracil, and leucovorin chemotherapy (FOLFOX4) in patients with stage

137 PV FUDR and systemic fluorouracil (FU) with leucovorin chemotherapy.

138 herapy with either intensive-course 5-FU and leucovorin combined with levamisole, or a standard regim

139 onal arm of INT0116, a fluorouracil (FU) and leucovorin-containing chemoradiotherapy regimen, is a st

140 rinotecan to the regimen of fluorouracil and leucovorin did not compromise the quality of life.

141 glucarpidase, inadequate initial increase in leucovorin dosing, and administration of glucarpidase mo

142 Leucovorin, due to its vitamin-like profile, has few sid

143 found that the combination of bortezomib and leucovorin enhanced caspase activation and increased apo

144 These data support leucovorin enhances the anti-cancer effect of bortezomib

145 in combination with i.v. 5-fluorouracil and leucovorin every 28 days.

146 e effects of postoperative fluorouracil plus leucovorin (five trials) or fluorouracil plus levamisole

147 nation chemotherapy regimen of folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (

148 tin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regim

149 ebo in combination with second-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) for metastatic

150 Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) is th

151 ancer and have been treated with combination leucovorin, fluorouracil, and oxaliplatin (FOLFOX)-based

152 tuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) reg

153 ther oxaliplatin-based chemotherapy (FOLFOX: leucovorin, fluorouracil, and oxaliplatin) or FOLFOX plu

154 in and fluorouracil; capecitabine; FOLFOX-4 (leucovorin, fluorouracil, and oxaliplatin); and modified

155 FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin; f

156 oup N9741, oxaliplatin plus fluorouracil and leucovorin (FOLFOX) also demonstrated a survival benefit

157 d improve on infused oxaliplatin with FU and leucovorin (FOLFOX) regimens.

158 ), oxaliplatin and infused fluorouracil plus leucovorin (FOLFOX), or irinotecan and oxaliplatin (IROX

159 t of CRC when combined with fluorouracil and leucovorin (FOLFOX).

160 itumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone, acc

161 tment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without b

162 bination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4).

163 (ASDs) and improvements in ASD symptoms with leucovorin (folinic acid) treatment have been reported i

164 f irinotecan plus high-dose fluorouracil and leucovorin for advanced colorectal cancer has led to the

165 to a widely used regimen of fluorouracil and leucovorin for metastatic colorectal cancer in terms of

166 had received protracted infusion of 5-FU and leucovorin for treatment of metastatic colon cancer.

167 Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the r

168 il (FU) an attractive alternative to FU plus leucovorin (FU/LV) for the adjuvant treatment of colorec

169 ection include intravenous fluorouracil with leucovorin (FU/LV) or oral capecitabine.

170 l compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-li

171 olong median survival over fluorouracil with leucovorin (FU/LV), and have supplanted FU/LV as the sta

172 rimidine clinical trials (bolus fluorouracil/leucovorin [FU/LV] and capecitabine) to test the hypothe

173 addition of oxaliplatin to fluorouracil plus leucovorin (FULV) improved disease-free survival (DFS) i

174 efficacy of adjuvant bolus fluorouracil and leucovorin (FULV) versus FULV with oxaliplatin (FLOX) in

175 d clinical dose regimen of 25 mg/kg/day 5-FU/leucovorin given i.v., both treatments were equally effi

176 equivalent to that in the fluorouracil-plus-leucovorin group (in the intention-to-treat analysis, P<

177 ents treated with irinotecan plus bolus 5-FU/leucovorin had a three-fold higher rate of treatment-ind

178 Although leucovorin had been shown to selectively spare normal bo

179 combination of irinotecan, fluorouracil, and leucovorin has also improved overall survival.

180 The combination of fluorouracil and leucovorin has until recently been standard therapy for

181 when added to irinotecan, fluorouracil, and leucovorin (IFL) in first-line metastatic colorectal can

182 receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of

183 to first-line irinotecan, fluorouracil, and leucovorin (IFL) significantly prolonged median survival

184 ith irinotecan, bolus fluorouracil (FU), and leucovorin (IFL).

185 ceive irinotecan and bolus fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and i

186 with irinotecan plus bolus fluorouracil and leucovorin (IFL; 3.7%; P = .04) or with bolus irinotecan

187 evacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with

188 , the prevalence of FRAs and the response to leucovorin in FRA-positive children has not been systema

189 ernational Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) st

190 alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.

191 was added to determine the MTD of 5-FU with leucovorin in the presence of 776C85.

192 e killing with complement and 5-fluorouracil/leucovorin in vivo, suggesting a new therapeutic approac

193 s most apparent in the subgroup treated with leucovorin, in which the level of TS expression and resp

194 resectable disease, modified 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) is

195 estigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI + B) in

196 IRINOX chemotherapy (comprising oxaliplatin, leucovorin, irinotecan, and fluorouracil) in patients wi

197 or those receiving induction 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).

198 ivity of PEGPH20 with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) wa

199 in the metastatic setting (eg, fluorouracil, leucovorin, irinotecan, and oxaliplatin and gemcitabine

200 cytotoxic combinations such as fluorouracil, leucovorin, irinotecan, and oxaliplatin as well as gemci

201 OL-F-IRIN-OX (combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) offers survival

202 FOLFIRINOX (fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin) and gemcitabin

203 ng FOLFIRINOX (5-fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin) and gemcitabin

204 sponse to chemotherapeutic regimens in which leucovorin is a component.

205 10 mg/m(2) PO bid) given with eniluracil and leucovorin is approximately 115-fold lower than the refe

206 atment with irinotecan plus fluorouracil and leucovorin is superior to a widely used regimen of fluor

207 Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon

208 5-fluorouracil, often given with leucovorin, is the most commonly used drug in colorectal

209 irinotecan plus infusional fluorouracil (FU)/leucovorin (LV) (FOLFIRI), irinotecan plus bolus FU/LV (

210 y 2, weekly; arm C, 5-FU 600 mg/m2 with oral leucovorin (LV) 125 mg/m2 hourly for the preceding 4 hou

211 mbinations of oxaliplatin, fluorouracil (FU)/leucovorin (LV) and irinotecan.

212 adiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone.

213 tion of oxaliplatin to fluorouracil (FU) and leucovorin (LV) improves the outcome of patients with co

214 ine and when added to fluorouracil (FU) plus leucovorin (LV) in first-line therapy of metastatic colo

215 d effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients wit

216 vorin, and oxaliplatin) versus infusional FU/leucovorin (LV) in this setting.

217 ; or arm 3 (bolus-only arm), with bolus FU + leucovorin (LV) in two 5-day cycles before and after XRT

218 n with fluorouracil (FU) and with or without leucovorin (LV) in various regimens.

219 5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal

220 1) and 5-fluorouracil (FUra) with or without leucovorin (LV) is their proven activity as single agent

221 motherapy with uracil and tegafur (UFT) plus leucovorin (LV) may reduce costs and complications assoc

222 eived either oral uracil/ftorafur (UFT) plus leucovorin (LV) or standard intravenous (IV) fluorouraci

223 es weekly: the dose of AMT was decreased and leucovorin (LV) rescue was added after the DLT was obser

224 alone or surgery plus fluorouracil (FU) and leucovorin (LV) to develop multigene algorithms to quant

225 ur and uracil in a 1:4 molar ratio (UFT) and leucovorin (LV) to intravenous (IV) fluorouracil (5-FU)

226 een recommended together with high-dose (HD) leucovorin (LV) to treat patients at risk for methotrexa

227 helial growth factor, plus fluorouracil (FU)/leucovorin (LV) versus FU/LV alone in patients with meta

228 Protocol C-03 compared adjuvant 5-FU and leucovorin (LV) with adjuvant MOF.

229 ficacy of oral uracil and tegafur (UFT) plus leucovorin (LV) with the efficacy of weekly intravenous

230 two irinotecan (CPT-11), fluorouracil (FU), leucovorin (LV), and oxaliplatin schedules in patients w

231 Fluorouracil (FU)-leucovorin (LV), irinotecan, and oxaliplatin administere

232 trials as a single agent or biomodulated by leucovorin (LV).

233 11; group A) or Oxal, fluorouracil (FU), and leucovorin (LV; group B).

234 ith irinotecan, bolus fluorouracil (FU), and leucovorin (LV; IFL) increased survival compared with IF

235 n combined with irinotecan/fluorouracil (FU)/leucovorin (LV; IFL).

236 X6 (bolus and infusion fluorouracil [FU] and leucovorin [LV] with oxaliplatin), bFOL (bolus FU and lo

237 es in the bolus/infusional fluorouracil plus leucovorin (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX4

238 omly assigned to bolus and infusional FU and leucovorin (LV5FU2), single-agent oxaliplatin, or the co

239 e (1004 patients) or bolus fluorouracil plus leucovorin (Mayo Clinic regimen; 983 patients) over a pe

240 ased therapy (either FU + levamisole or FU + leucovorin; n = 229) versus no postsurgical treatment (n

241 eks, with modified doses of fluorouracil and leucovorin on the first four and the last three days of

242 before cycle 1; methotrexate 3.5 g/m(2) with leucovorin on weeks 1, 3, 5, 7, and 9; TMZ daily for 5 d

243 le to metabolize folinic acid (also known as leucovorin or 5-formyltetrahydrofolate), whose metabolic

244 r first-line fluoropyrimidines (fluorouracil/leucovorin or capecitabine, the latter only for metastat

245 ed venous infusion CT (n = 325), RT + FU +/- leucovorin or levamisole bolus CT (n = 1,695), or CT alo

246 were randomly assigned to bolus fluorouracil/leucovorin or protracted venous infusion fluorouracil.

247 and in combination with 5-fluorouracil plus leucovorin or with oxaliplatin.

248 us intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alo

249 vents consistent with those expected from FU/leucovorin- or IFL-based regimens were seen, as were mod

250 There is no advantage to leucovorin- or levamisole-containing regimens over bolus

251 In combination with 5-fluorouracil and leucovorin, oxaliplatin provides a higher response rate

252 eived 4 preoperative cycles of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) followed b

253 chaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prosp

254 l (OS) benefit from infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus

255 bevacizumab, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) show

256 rvival are similar to those observed with FU/leucovorin/oxaliplatin combinations.

257 fewer adverse events than fluorouracil plus leucovorin (P<0.001).

258 of body-surface area per day, plus 20 mg of leucovorin per square meter per day, for five days, foll

259 of three chemotherapy regimens: the low-dose leucovorin plus FU (Mayo Clinic; LDLV) regimen, the high

260 U (Mayo Clinic; LDLV) regimen, the high-dose leucovorin plus FU (Roswell Park; HDLV) regimen, and the

261 oswell Park; HDLV) regimen, and the low-dose leucovorin plus levamisole plus FU (LDLV plus LEV) regim

262 FU plus levamisole was inferior to 5-FU plus leucovorin plus levamisole when treatment was given for

263 val compared with intensive-course 5-FU plus leucovorin plus levamisole.

264 Since 2003, fluorouracil/leucovorin plus oxaliplatin (FOLFOX) has been the standa

265 h compared standard bolus fluorouracil (FU), leucovorin, plus irinotecan (IFL) with infused FU, leuco

266 orin, plus irinotecan (IFL) with infused FU, leucovorin, plus oxaliplatin (FOLFOX4) and irinotecan pl

267 A high 42-hour plasma MTX to leucovorin ratio (measure of MTX exposure) was associate

268 evel of TS expression and response to FU and leucovorin reached statistical significance (P =.034).

269 e (MTX/AZA) or intravenous methotrexate with leucovorin rescue (I.V. MTX) every 2 weeks for 6 months.

270 and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) ph

271 domly assigned to receive high-dose MTX with leucovorin rescue or escalating dose MTX with PEG aspara

272 es of vinblastine, methotrexate with calcium leucovorin rescue, and fluorouracil (VbMF).

273 py that included high-dose methotrexate with leucovorin rescue, doxorubicin, cisplatin, bleomycin, cy

274 e doses of intravenous (IV) glucarpidase and leucovorin rescue.

275 and methotrexate (400 mg/kg per cycle) with leucovorin rescue.

276 ating dose MTX with PEG asparaginase without leucovorin rescue.

277 t change after adjustment for age or dose of leucovorin rescue.

278 treatment with irinotecan, fluorouracil, and leucovorin resulted in significantly longer progression-

279 Adjuvant chemoradiation with 5-fluorouracil/leucovorin significantly improves disease-free survival

280 Interestingly, leucovorin supplementation of a commonly used folate-def

281 treatment with irinotecan, fluorouracil, and leucovorin than during treatment with fluorouracil and l

282 ich stands for folate utilization enzyme for leucovorin), that is hypersusceptible to antifolates.

283 olerated dose (MTD) of 5-FU, with or without leucovorin, that could be safely administered with 776C8

284 on could be detected between the addition of leucovorin to FU and the level of TS expression in the p

285 ropyrimidine dehydrogenase [DPD]), 5-FU, and leucovorin to simulate this schedule.

286 cetaxel, cisplatin, fluorouracil (5-FU), and leucovorin (TPFL5) induction chemotherapy for patients w

287 ents were equally efficacious, although 5-FU/leucovorin treatment started 7 days earlier.

288 al rates in comparison with fluorouracil and leucovorin treatment.

289 ompared with treatment with fluorouracil and leucovorin, treatment with irinotecan, fluorouracil, and

290 type of pre/postoperative chemotherapy (5-FU-leucovorin vs. FOLFOX/FOLFIRI vs. bevacizumab) (P=0.11)

291 of oxaliplatin and infused fluorouracil plus leucovorin was active and comparatively safe.

292 Systemic fluorouracil (5-FU) plus leucovorin was added to intrahepatic FUDR to prolong the

293 However, transport of the reduced folate leucovorin was not detected for either the wild-type or

294 y (capecitabine or infused fluouroracil plus leucovorin) was decided before randomisation.

295 Fluorouracil and leucovorin were administered before, during, and after r

296 then intravenous chemotherapy with 5-FU plus leucovorin were administered until maximal regression of

297 new agent oxaliplatin to high-dose 5FU plus leucovorin, which gave a median survival rate of 12.5 mo

298 CDB 402 of folinic acid, known clinically as leucovorin, which is a reduced form of the folic acid pr

299 Chemotherapy consisted of fluorouracil and leucovorin with 45 Gy in 25 fractions with a 5.40-Gy boo

300 combination of irinotecan, fluorouracil and leucovorin with bolus doses of fluorouracil and leucovor